Who owns Organon?

In 2007, the Dutch pharmaceutical company Organon underwent a significant transformation when it was acquired by Schering-Plough, a multinational corporation. This acquisition marked the beginning of a new era for Organon, as it became part of a larger organization with global reach and resources.

Two years later, in 2009, Schering-Plough itself underwent a major change as it merged with MSD, which is known in the United States as Merck & Co. Inc. This merger created a formidable player in the pharmaceutical industry, with a strong portfolio of drugs and a global footprint.

Following the merger, Organon, now as part of MSD, continued to operate in the pharmaceutical space, leveraging the resources and expertise of its new parent company. MSD, based in Kenilworth, New Jersey, is a well-respected name in the industry, known for its commitment to innovation and quality.

In Switzerland, however, Schering-Plough operated under a different name: Essex Chemie. This allowed the company to maintain a distinct identity and presence in the Swiss market, catering to the specific needs and regulations of the region.

The acquisition of Organon by Schering-Plough and subsequent merger with MSD demonstrate the dynamic nature of the pharmaceutical industry. Companies are constantly seeking growth and expansion through mergers and acquisitions, creating stronger and more diversified entities.